In BREAKWATER, EC plus FOLFIRI achieved a 64.4% response rate and showed a trend toward improved overall survival in patients ...
Pfizer Inc. (NYSE: PFE) today announced positive results from Cohort 3, a separate randomized cohort of the pivotal ...
MedPage Today on MSN
Targeted duo wins again in BRAF-mutant colorectal cancer
SAN FRANCISCO -- Including encorafenib (Braftovi) and cetuximab (Erbitux) in the first-line treatment of BRAF V600E-mutated ...
Colorectal cancer is the third most common cancer globally, with approximately 1.8 million people diagnosed in 2022 ...
With durable responses, encouraging survival outcomes, and evidence that some patients may become eligible for ...
BRAF-positive non-small cell lung cancer (NSCLC) treatments can use the BRAF biomarker to provide effective, targeted treatment for this subset of lung cancer. BRAF-positive NSCLC is an uncommon or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback